Cardiomyopathy was not more prevalent in carriers of heterozygous MYZAP LoF variants (2/26; 7.7%) compared with individuals without MYZAP variants (1420/15 552; 8.4%; χ2 test: odds ratio, 0.91 [95% CI, 0.15–3.14]). Here, MYZAP is linked to cardiomyopathy.